^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Thyroid Gland Medullary Carcinoma
    Drug:Caprelsa (vandetanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    02/16/2012
    Excerpt:
    Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Medullary Thyroid Carcinoma...Vandetanib and cabozantinib, oral kinase inhibitors, are recommended for the treatment of medullary carcinoma in patients with unresectable locally advanced or metastatic disease…